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Epigenetics has become the indispens-
able science for understanding the gene-
environment relationships that control
risk exposure, therapeutic response, and
disease progression. Despite the impor-
tance of the field, not all scientists agree
on how even to define epigenetics (Dupont
et al., 2009); some, like me, restrict epige-
netics to events that happen at the gene
level, such as DNA methylation and his-
tone modifications that constitute epige-
netic marks, and the binding of proteins
and RNAs involved in transcription con-
trol. Others also include miRNAs that
interact with messenger RNAs. My pur-
pose here is not to discuss semantics, but
rather to consider the enormous expecta-
tions that we have placed upon epigenetics
for its potential to provide quantifiable
markers of risk.
The notion of risk itself is a mat-
ter of significant debate in public health.
It relies on our capacity to determine
when a cell or tissue has become altered
to the point where a disease might have
a chance of onset, recurrence, progres-
sion or resistance to treatment. Risk
is also linked to statistics; individuals
who display a known marker of risk
are placed in an “at risk” group from
which, usually, only some people will
actually develop the disorder. Therefore,
to address uncertainty associated with
risk assessment, the individual “at risk”
should be monitored, and we should pri-
oritize the search for underlying mech-
anisms in order to develop prevention
strategies.
Next-generation sequencing is cur-
rently the basis for large scale epige-
netic analyses. But the balance between
the investment of large amounts of funds
in genetic sequencing and the paucity
of resulting new information for cancer
knowledge has raised doubt about the
overall efficiency of this approach (Yaffe,
2013). With the epigenetic code consist-
ing of more than two-dozen different epi-
genetic marks, the gathering of data for
risk assessment would require an expo-
nential use of such costly technologies.
Nonetheless, in my opinion, epigenetics is
likely to enable great strides in risk assess-
ment because epigenetic marks are rapidly,
and sometimes sustainably, modified in
response to risk variations. The highly spe-
cific nature of the mechanisms that con-
trol epigenetic marks might even provide
targets for strategies designed to reduce
individual risk.
Indeed, our query should not be
merely whether epigenetics can contribute
to risk assessment, but how the infor-
mation that we learn can and will be
used to provide meaningful measures
of risk. However, as developed in the
next paragraphs, epigenetic information is
unlikely to function as a sufficient sin-
gle factor in risk assessment. Moreover,
the epigenome that comprises epigenetic
marks for all genes is development-
dependent as well as tissue-dependent.
Thus, a sound experimental approach is
necessary to identify suitable sources of
tissue for epigenetic analysis and to bet-
ter understand how the epigenome would
respond depending on the time period of
risk exposure.
THE PLACE OF EPIGENETICS IN RISK
ASSESSMENT
Genetic and epigenetic modifications
ought to be considered together in risk
investigations. Risk assessment for disease
development has been conducted via
screening for genetic modifications in
cancers, cystic fibrosis, heart disorders,
etc. Yet, the risk level can span a wide-
range; for example, BRCA1 mutation
carriers have between 56 and 80% life-
time risk for breast cancer (Millot et al.,
2012). Epigenetics is now considered a
missing link in risk estimation that nor-
mally relies on genetics, as in the case
for mood disorders (Menke et al., 2012).
In these diseases, as well as in multiple
sclerosis and many cancers, heritability
cannot be explained only by genetic risk
factors (Zhou et al., 2014). The discov-
ery of epigenetic mechanisms involved
in pathogenesis provides a new option
for risk assessments. The combination of
genetic and epigenetic markers confers an
enhanced risk appreciation. For instance,
survival from non-small cell lung can-
cer appears better estimated by RGC32
methylation and TP53 mutations together
compared to mutations alone (Kim et al.,
2011). These findings are encouraging.
Nevertheless, making epigenetics a use-
ful part of risk assessment will require
well-developed and coordinated efforts. As
pointed out by Liloglou and colleagues, for
example, the sensitivity of a given assay is
a major aspect in determining risk; there-
fore, better results might be obtained in
a first approach with populations at high
risk rather than the general population if
the test is not highly sensitive. Also, the
epigenetic field has been mainly devel-
oped via fundamental research; in order
to properly utilize epigenetic marks in
risk assessment, we need to develop epige-
netic studies aimed at clinical biomarker
discovery and validation (Liloglou et al.,
2014).
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Epigenetic modifications are the prin-
cipal engine for changes of cell behavior
and organ development (Weaver, 2009;
Parfitt and Zernicka-Goetz, 2010), sug-
gesting that it is paramount to study
risk exposure in the appropriate con-
text. For instance, epigenetic modifica-
tions have been associated with the impact
of intrauterine growth restriction on lung
disease via the involvement of genes, like
PPARγ , necessary for lung development
(Joss-Moore et al., 2011). Also, the real
impact of epigenetic marks on the onset
of toxicant-induced risk is still unclear
(Alyea et al., 2012); improved knowl-
edge of the role of epigenetic modifi-
cations on normal cell function should
further this understanding. Overall, epige-
netic research on non-diseased tissues is
lacking. The National Institutes of Health
Epigenomics Mapping Consortium may
help fill part of the gap by promoting the
gathering of epigenomic information from
stem cells as well as primary ex vivo tissues
representing normal conditions (Bernstein
et al., 2010); still few studies make use of
functional models of normalcy, especially
for human tissues. A serious effort should
be devoted to building and implement-
ing models via, for instance, the design of
organs-on-chips for laboratory use (Vidi
et al., 2013). Moreover, because the epige-
netic code is specific to each tissue type, we
must carefully choose in vitro cell models
as well as clinical specimens to study the
contribution of epigenetic modifications
in pathology.
ORIGIN OF RISK AND CONSEQUENCES
ON THE ASSESSMENT METHOD
Logically, some risk is engraved in the tis-
sue where disease starts; thus, in a first
approach, this tissue should be the main
location to study the epigenetic modi-
fications that lead to altered cell func-
tions preceding, as well as during, a
disease. Increasing evidence shows that
risk for chronic diseases might be estab-
lished from birth or by environmen-
tal impact during childhood (Joss-Moore
et al., 2011; Teegarden et al., 2012).
Epigenetic remodeling, a normal process
during organ development, makes the
epigenome particularly sensitive to envi-
ronmental impact. Moreover, epigenetic
modifications can be carried within chro-
matin through mitotic division, indicating
that sustained epigenetic marks in tissues
of disease onset are good candidates for
risk assessment. However, while prognosis
on disease progression or treatment out-
comes of a clinically established disease
can usually be measured directly from the
disease site itself, as part of the treatment
process via biopsy or surgery, in primary
prevention invasive or remote tissue access
would be an issue for the assessment of risk
for a clinically undetectable disease.
Whenever possible, a solution to the
tissue sampling challenge is to initially
carry out research on biopsy sections to
decipher the local epigenome associated
with a risk of specific disease; subse-
quently, we would identify blood markers
that mirror the altered epigenetic sta-
tus of the targeted organ. This situation
might occur if the environmental impact
on risk development introduced not only
epigenetic changes in the organ site of
the disease, but also direct modifications
in the blood detectable by metabolomics
or even epigenomics. Although epigenetic
modifications in blood cells are primar-
ily specific to this tissue and should be
used with caution to prevent mislead-
ing risk assessment for another tissue,
there might be instances for which these
FIGURE 1 | Potential blood markers reflecting epigenetic changes of disease risk. An
environmental factor or risk exposure is a powerful means to modify the epigenome in certain
organs and cell populations. Three non-exhaustive and non-exclusive options to detect the risk in
the blood-stream include (i) blood metabolites or epigenetic modifications directly triggered by the
environmental factor that also induced epigenetic modifications in the “at risk” or diseased organ,
(ii) metabolites released into the blood-stream by the epigenetically-modified organ with increased
risk for disease, and (iii) miRNAs synthesized upon environmental factor-mediated epigenetic
modifications in the “at risk” or diseased organ and released into the blood-stream.
modifications could indeed be of use fol-
lowing sound confirmation studies. For
example, similar epigenetic changes that
target a set of genes involved in brain
disorders like schizophrenia have been
observed in both brain cells and periph-
eral lymphocytes (Guidotti et al., 2014).
Blood markers might also be usable if
the epigenetic modifications in the tar-
get organ have changed cellular activity in
such a way that it is accompanied by the
release of a specific set of blood metabo-
lites or miRNAs (Figure 1). Indeed, blood-
based detection of miRNAs has been used
to reveal cancers (Liloglou et al., 2014)
and the risk of aggressive neoplasia (Boeri
et al., 2011).
Importantly, the modification of epige-
netic marks by a risk or protection factor
at any given time will depend on the epige-
netic soil determined by the history of the
individual in terms of ancestry and the life
events that keep shaping the epigenome.
Taking into account such epigenetic his-
tory is necessary to optimally ascertain the
level of risk.
THE VALUE OF EPIGENETIC HISTORY
An uncanny power of epigenetic marks lies
in their propensity to carry an increased
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level of either protection or risk as set by
the lifestyle of an individual’s ancestor if
these epigenetic modifications affected the
gametes. This possibility has been reported
for hypothalamic-pituitary-adrenal axis
dysregulation and altered response to
stress in offspring following stress peri-
ods in male rats induced before breed-
ing. In this study, changes in the level
of gene transcripts, notably of miRNAs,
in brain regions that control stress were
suggested to be evidence of epigenetic
modifications of these genes in offspring
(Rodgers et al., 2013). Moreover, the
mother’s lifestyle (e.g., nutrition, stress)
during pregnancy also influences the off-
spring’s epigenome (Vanhees et al., 2014).
How long the impact has to be present
to permanently engrave the genome is
unclear. Nonetheless, it is undeniable that
the epigenetic soil created by ancestry
determines future epigenetic responses to
environmental factors (Joss-Moore et al.,
2011) and behaviors. In light of this grow-
ing evidence, I would argue that under-
standing the epigenetic soil should also be
considered an integral part of risk assess-
ment methods for individuals.
The complexity of the epigenetic code
also implies its power and utility for
risk assessment; it might permit the mea-
surement of epigenetic marks of differ-
ent strengths (e.g., temporary, stable) and
thus, provide a means by which we can
determine the origin of risk or whether
an individual may react to a given envi-
ronmental factor. This reasoning is not a
futuristic view of medicine through which
individuals would be aware of their level of
protection against a particular disease, but
rather follows from growing evidence that
epigenetics will soon become an extremely
precise tool for improving wellness.
However, the efficiency of risk assess-
ment using epigenetic screens will be low
unless experiments are carefully designed.
For instance, comprehensive mapping of
epigenetic modification sites will not help
us understand disease risk unless nor-
mal variation at epigenetic sites is also
investigated, taking into account eth-
nicity/race and even sociocultural back-
ground. Finally, the necessity to compare
results on potential biomarkers of risk via
meta-analyses is rendered difficult because
of the plethora of methods used in epige-
netics. Current and future databases that
concentrate epigenetic data should use
researcher-agreed upon standards, includ-
ing clearly documented information on
the means by which data were acquired.
CONCLUSION
Risk assessment in healthcare remains a
coveted yet unachieved goal. Our under-
standing of epigenetic marks offers a
unique potential to personalize risk assess-
ment and individualize treatment of dis-
eases that rely on gene expression control
for their onset and progression.
The care for most chronic diseases
could be significantly improved by focus-
ing on epigenetics in research, though we
should not pursue epigenetic data for risk
assessment without initiating discussions
on the ethical impact of such endeav-
ors. Through this statement, I wish to
spur our thinking about the consequences
of collecting potentially deep knowledge
of a person’s epigenome. For individuals
who are clinically ill, epigenetic informa-
tion is emerging as undoubtedly useful
for treatment decisions. Once risk assess-
ment pertains to the prevention of dis-
ease onset, epigenetic information will
also come from disease-free individuals,
concomitantly providing a mine of data
on their ancestry and lifestyle. In addi-
tion to the protection of epigenetic data,
risk assessment should be accompanied
with a plan to reduce the risk of disease
onset in agreement with the World Health
Organization best practices for screening.
Also, if samples from healthy individuals
were only collected for epigenetic research
purposes, it would seem logical that, as
new risk assessment tools become avail-
able, research subjects themselves are given
the possibility, if they wish, to access and
potentially gain benefit from this informa-
tion. This option would require that indi-
viduals participating in risk assessment
be given the choice to be contacted in
case new information gathered from the
research becomes of use to them. In other
words, more than ever before, risk assess-
ment based on epigenetic history should
embrace a relation of trust between sci-
entists, (potential) patients and healthcare
providers.
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